Topical drug bioavailability, bioequivalence, and penetration / red. V.P.Shah. - 2nd ed. - New York: Springer Science+Business Media, 2014. - xiii, 402 p. : ill. - Bibliogr. at the end of the chapters. - Ind.: p.399-402. - ISBN 978-1-4939-1288-9 Шифр: (И/Р28-T75) 02  Место хранения:   02 | Отделение ГПНТБ СО РАН | Новосибирск

Оглавление / Contents

Part I. Percutaneous Absorption 1 Percutaneous Absorption ...................................... 3 Michael S. Leo and Howard I. Maibach 2 Animal Modeis for Percutaneous Absorption ................... 21 Eui Chang Jung and Howard I. Maibach 3 Mitigating Dermal Exposure to Agrochemicals ................. 41 Robert P. Chilcott Part II. In Vitro Drug Release 4 Importance of In Vitro Drug Release ......................... 61 Vinod P. Shah and Roger L. Williams 5 Diffusion Cell Design ....................................... 79 Jon R. Heylings 6 In Vitro Product Quality Tests and Product Performance Tests for Topical and Transdermal Drug Products ............. 81 Avraham Yacobi, Clarence T. Ueda and Vinod P. Shah 7 Safety and Efficacy Testing of Topical Products; Practical Considerations .............................................. 91 Rashmikant Mohile Part III. Bioequivalence of Topical Drug Products 8 Challenges in Evaluating Bioequivalence of Topical Dermatological Drug Products ............................... 101 Vinod P. Shah and Roger L. Williams 9 Methods for the Assessment of Bioequivalence of Topical Dosage Forms: Correlations, Optimization Strategies, and Innovative Approaches .................................. 113 Isadore Kanfer 10 Application of Microdialysis in Assessing Cutaneous Bioavailability ............................................ 153 Eva Benfeldt Part IV. Bioequivalence: Targeted Drug Delivery 11 Follicular Drug Penetration ................................ 169 Jürgen Lademann and Alexa Patzelt 12 Development of Pilosebaceous Unit-Targeted Drug Products ... 181 Guang Wei Lu, Kevin S. Warner and Fangjing Wang 13 Deep Percutaneous Penetration into Muscles and Joints: Update ..................................................... 217 Vladyslava Doktor, Christine M. Lee and Howard I. Maibach 14 Efficacy and Toxicity of Microneedle-Based Devices ......... 237 Michael S. Leo, Hadar A. Lev-Tov, Faranak Kamangar, Howard I. Maibach and Raja K. Sivamani Part V. Transdermal Drugs and Modelling 15 Mathematical Models for Topical and Transdermal Drug Products ................................................... 249 Yuri G. Anissimov and Michael S. Roberts 16 Transdermal Patches: An Industrial Perspective on the Relevance of In Vitro Skin Permeation Studies and Approaches on Design of Manufacturing Processes ........ 299 Björn Schurad and Marieke Gosau 17 Transdermal Drug Delivery Systems .......................... 319 Vinod P. Shah and Roger L. Williams Part VI. Clinical Studies and Bioequivalence 18 Dermal Estradiol and Testosterone Transfer in Man: Existence, Models, and Strategies for Prevention ........... 331 Aaron Gandhi, K. L. Busse and Howard I. Maibach 19 Effects of Occlusion on Dermal Drug Delivery: Implications for Bioequivalence Measurement ............................. 351 Nilab Osman and Howard I. Maibach 20 Challenges with Clinical Endpoints - Bioequivalence ........ 361 Garrett Coman, Nicholas Blickenstaff and Howard I. Maibach 21 Clinical Considerations of Bioequivalence for Topical Dermatologie Drugs ......................................... 371 Jessica Schweitzer and Howard I. Maibach Part VII. Guidelines and Workshop Report 22 OECD Test Guideline 428 - A Method for In Vitro Percutaneous Absorption Measurement? ....................... 381 John Jenner 23 Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products: Current Challenges and Future Prospects .................................................. 389 Vinod P. Shah, Avraham Yacobi and Majella E. Lane Index ......................................................... 399